Encellin, a regenerative medicine biotech company founded at the University of California San Francisco (UCSF), and developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round.
ALT UCSF researcher Tejal Desai, one of the founding team.